PIONEERING
A NEW GENERATION OF NEUROLOGICAL DISEASE TREATMENTS
Axial Therapeutics is fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Clinical Trial
Axial’s lead product candidate, AB-2004, is a gut-restricted molecular therapy being studied for the treatment of irritability associated with autism in a Phase 2b trial. >> Learn More
At Axial, we are at the forefront of scientific innovation in the gut microbiome and its intersection with neurodegenerative diseases and neurodevelopmental disorders. We are dedicated to improving the lives of people with conditions such as Autism Spectrum Disorder and Parkinson’s disease by leveraging our understanding of the role of the microbiome and its impact on the nervous system.
Axial Therapeutics Biotechnology Company
Axial’s novel therapeutic approach is focused on the development of small molecule drugs with defined mechanisms of action that act on new targets in the gut to mitigate the impact of metabolites and bacteria linked to the pathology, progression, and symptoms of neurological diseases and disorders.
OUR SCIENCE
Our scientific focus on the microbiome gut-brain axis represents a transformative therapeutic approach that has potential to treat neurological diseases and disorders in ways never before possible.
OUR PIPELINE
We are advancing a pipeline of gut-targeted small molecule therapies in areas of significant unmet patient need including autism and Parkinson’s disease, with a recent expansion into oncology.
ABOUT US
At Axial, we are dedicated to the delivery of novel medical interventions that are borne from scientific rigor and make a meaningful difference in the lives of patients with neurological diseases and disorders.
